Alzheonincis A Clinical Stage Biopharmaceutical Company Based In Framinghammassachusettsfounded In July 2013 By Martin Tolarmdphdthe Company Is Dedicated To Developing Disease Modifying Therapies For Alzheimerae S Disease And Other Neurodegenerative Disordersfocusing On Protein Misfolding And Aggregationalzheon Aims To Advance Precision Medicine To Help Preserve Cognitive Function And Memory In High Risk Patient Populations The Company Specializes In Repurposing And Optimizing Clinical Stage Drug Candidatesparticularly Targeting Amyloid Aggregation And Neurotoxicityits Key Productvaliltramiprosatealz 801 Is An Oral Agent Designed To Inhibit Neurotoxic Amyloid Aggregationalzheon Has Made Significant Progress In Clinical Trialsincluding Completing Phase 2 Biomarker Studies And The Apolloe4 Phase 3 Trial For Early Symptomatic Alzheimerae S Patientsthe Company Has Received Substantial Fundingincluding $51 Million In Grants From The National Institute On Agingto Support Its Development Efforts
No conferences found for this company.
| Company Name | Alzheon Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
